June 25, 2020

SWOG S1505: results of chemotherapy (mFOLFIRINOX) versus perioperative Gemcitabine / nab-Paclitaxel for resectable pancreatic ductal adenocarcinoma (PDA)

The authors concluded that there is little evidence that either regimen improves overall survival compared to the historical pattern of treatment. SWOG S1505 is a prospective, […]
June 24, 2020

Lifileucel cell therapy demonstrates efficacy in highly pretreated metastatic melanoma patients

Results indicate an overall response rate of 36.4% and a safety profile consistent with the disease Therapeutic options for patients with advanced melanoma, especially those who […]
June 22, 2020

Pembrolizumab plus axitinib in first-line continue to demonstrate superiority compared to sunitinib in patients with clear cell renal cell carcinoma

Updated data from the KEYNOTE-426 trial was presented at the ASCO 2020 Virtual Annual Meeting Previous results from KEYNOTE-426, a phase III randomized, open-label trial (NCT02853331), […]
June 19, 2020

Prevalence and association of ARID1A in driver changes and in biomarkers of immune coreceptor inhibitors in patients with non-small cell lung cancer

Recent data suggest that the tumor suppressor gene ARID1A is associated with high antitumor immunity and may be a predictive biomarker of response to immunotherapy in […]
June 16, 2020

PANDA study demonstrates progression-free survival gain for FOLFOX + panitumumab and 5FU / LV + first-line panitumumab to RAS-BRAF wild-type elderly metastatic colorectal cancer patients

5FU / LV plus panitumumab for up to 12 cycles, followed by maintenance of panitumumab until disease progression may be a reasonable option in elderly patients […]
June 15, 2020

Preliminary results of the use of tipifarnib demonstrate encouraging activity in solid tumors with mutant HRAS

Phase II trials evaluated the activity of tipifarnib in squamous carcinomas, tumors of the thyroid and salivary glands, urothelial carcinomas, among others HRAS is an overexpressed […]
June 9, 2020

KEYNOTE-204 trial demonstrates significant improvement in progression-free survival of patients with relapsed or refractory classic Hodgkin’s lymphoma treated with pembrolizumab

Results presented at ASCO 2020 evaluated pembrolizumab versus brentuzimab vedotin With clinically significant results, a phase III KEYNOTE-204 trial, presented at the ASCO 2020 Virtual Annual […]